

**Chimeric antigen receptor T-cell therapy for a patient
Philadelphia chromosome-positive acute lymphoblastic
leukemia with leukoencephalopathy who relapsed after
bone marrow transplantation**

Journal:	<i>Pediatric Blood & Cancer</i>
Manuscript ID	PBC-22-0245.R1
Wiley - Manuscript type:	Letter to the Editor
Date Submitted by the Author:	n/a
Complete List of Authors:	Kawabata, Naoko; Graduate School of Medicine, Kyoto University, pediatrics Hiramatsu, Hidefumi; Graduate School of Medicine, Kyoto University, Department of Pediatrics Mikami, Takashi; Graduate School of Medicine, Kyoto University, pediatrics Akazawa, Ryo; Graduate School of Medicine, Kyoto University, pediatrics Tanaka, Kuniaki; Graduate School of Medicine, Kyoto University, Department of Pediatrics Kozuki, Kagehiro; Graduate School of Medicine, Kyoto University, pediatrics Kubota, Hirohito; Graduate School of Medicine, Kyoto University, Department of Pediatrics Saida, Satoshi; Graduate School of Medicine Kyoto University, Pediatrics Kato, Itaru; Graduate School of Medicine, Kyoto University, pediatrics Umeda, Katsutsugu; Graduate School of Medicine, Kyoto University, pediatrics Hirate, Tomoaki; Gifu Municipal Hospital, pediatrics Kanda, Kaori; Gifu Municipal Hospital, pediatrics Adachi, Souichi; Graduate School of Medicine, Kyoto University, Human Health Sciences Takita, Junko; Graduate School of Medicine, Kyoto University, pediatrics
Keywords:	chimeric antigen receptor T-cell therapy, leukoencephalopathy, relapsed Philadelphia chromosome positive acute lymphoblastic leukemia

SCHOLARONE™
Manuscripts

LETTER TO THE EDITOR

Chimeric antigen receptor T-cell therapy for a patient Philadelphia chromosome-positive acute lymphoblastic leukemia with leukoencephalopathy who relapsed after bone marrow transplantation

Naoko Kawabata¹, Hidefumi Hiramatsu¹, Takashi Mikami¹, Ryo Akazawa¹, Kuniaki Tanaka¹, Kagehiro Kozuki¹, Hirohito Kubota¹, Satoshi Saida¹, Itaru Kato¹, Katsutsugu Umeda¹, Tomoaki Hirate², Kaori kanda², Souichi Adachi³, and Junko Takita¹

¹Department of Pediatrics Graduate School of Medicine, Kyoto University.

²Department of Pediatrics, Gifu Municipal Hospital.

³Department of Human Health Sciences, Graduate School of Medicine, Kyoto University.

Corresponding author: Hidefumi Hiramatsu

Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

Phone: +81-75-751-3290; Fax: +81-75-752-2361

Email address: hiramatu@kuhp.kyoto-u.ac.jp

Word counts: main text, 844 words

Number of tables and figures: 0 tables; 1 figure; 1 supporting information file.

A short running title: CAR T-cell therapy for ALL with leukoencephalopathy

24

25 Key words: chimeric antigen receptor T-cell therapy, leukoencephalopathy, relapsed

26 Philadelphia chromosome-positive acute lymphoblastic leukemia

27

28 **Abbreviations**

ALL	acute lymphoblastic leukemia
ASTCT	American Society for Transplantation and Cellular Therapy
BBB	blood–brain barrier
CAR	chimeric antigen receptor
CNS	central nervous system
CR	complete remission
CRS	cytokine release syndrome
CSF	cerebrospinal fluid
ICANS	immune-related effector cell-associated neurotoxicity syndrome
LP	lumbar puncture
mPSL	methylprednisolone
MRD	minimal residual disease

MRI	magnetic resonance imaging
TIT	triple intrathecal therapy

29

For Peer Review

To the editor:

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy was developed for refractory and/or multiply relapsed B-cell precursor acute lymphoblastic leukemia (ALL). However, CAR T-cell therapy may cause systemic cytokine release syndrome (CRS) and immune-related effector cell-associated neurotoxicity syndrome (ICANS)¹⁻³. The symptoms of ICANS include fatal cerebral edema^{2,4}. Patients with active and symptomatic central nervous system (CNS) disease were excluded from the study as multiple deaths due to cerebral edema occurred during an anti-CD19 CAR T-cell treatment trial⁵⁻⁷.

We report a post-transplant relapsed case of a 14-year-old girl with Philadelphia chromosome-positive ALL who was diagnosed with symptomatic leukoencephalopathy. She was first treated with dasatinib-combined multi-drug chemotherapy regimen when she was 11 years old, but she experienced a relapse during the reinduction phase in January 2019. She achieved a second hematological complete remission (CR) with salvage chemotherapy consisting of a hyper-CVAD regimen, ponatinib, and two cycles of blinatumomab⁸. In November 2019, the patient underwent unrelated bone marrow transplantation, resulting in a second relapse affecting the CNS with minimal residual disease (MRD) in the bone marrow. After achieving a third CR with blinatumomab and triple intrathecal therapy (TIT), CAR T-cell therapy was planned. A decline in cognitive function and language impairment were observed while maintaining CR with bridging chemotherapy consisting of ponatinib, 6-mercaptopurine, weekly vincristine, and bi-weekly TIT. Cranial magnetic resonance imaging (MRI) showed disseminated necrotizing leukoencephalopathy, suggesting active demyelinating lesions (Figs. 1A and 1B). As active leukoencephalopathy may result in severe neurotoxicity, tisagenlecleucel was postponed until leukoencephalopathy improved. As bridging chemotherapy, a mini hyper-CVAD regimen and

ponatinib were administered⁹. On day 21, follow-up MRI showed an improvement of leukoencephalopathy (Figs. 1C and 1D), and her speech and cognitive function gradually improved. The lumbar puncture (LP) before CAR T-cell infusion was normal; a bone marrow aspiration showed bcr-abl negative and flow cytometry-based MRD negative CR.

After lymphodepletion chemotherapy with cyclophosphamide and fludarabine, the patient received a single dose of tisagenlecleucel (total cell dose: 0.9×10^8) 7 months after the second relapse (day 1). On day 4, she developed fever $\geq 38.0^\circ\text{C}$, grade 3 headache and grade 2 tachycardia, abdominal pain, vomiting, and diarrhea according to the Common Terminology Criteria for Adverse Events version 5¹⁰; antipyretics and broad spectrum antibiotics were initiated. She shortly developed hypertension, and her C-reactive protein level increased to 35.1 mg/dL on day 5. These symptoms indicated grade 1 CRS, for which tocilizumab (8 mg/kg) is recommended, according to the American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus Grading^{2,11}. Despite two additional doses of tocilizumab and the initiation of 2 mg/kg/day methylprednisolone (mPSL), her symptoms worsened on day 6. Dysphasia, anxiety, and a low level of consciousness were also present. On day 7, a grade 3 seizure occurred; midazolam was initiated under mechanical ventilation. Although computed tomography scans of the brain did not show edema, the opening and closing cerebrospinal fluid (CSF) pressures during LP were $>30 \text{ cmH}_2\text{O}$, which were markedly high. Mononuclear and polynuclear cell counts and protein levels in the CSF were elevated. Fluorescence-activated cell sorting of the CSF showed that 7.8% of the $\text{CD}3^+$ cells were CAR T-cells (Supplemental Figure S1). On day 8 and after the fourth administration of tocilizumab, fever resolved, and her blood pressure returned to normal. On day 12, although the follow-up MRI showed exacerbation of leukoencephalopathy (Figs. 1E and 1F), her symptoms continued to improve; thus, mPSL was

tapered off on day 15. On day 26, LP was performed, which showed a normal CSF, and MRI findings on day 30 revealed improvement of leukoencephalopathy (Figs. 1G and 1H). Twelve months after CAR T-cell infusion, she maintained CR and her cognitive function improved.

In this patient, distinguishing neurological changes as symptoms of ICANS from exacerbation of leukoencephalopathy was challenging because most symptoms overlapped. When the CRS

began to resolve on day 7, the seizure occurred. According to the ASTCT ICANS Consensus

Grading, the elevated intracranial pressure indicated grade 4 neurotoxicity². Increased protein

concentration and leukocyte and CAR T-cell infiltration into the CSF in patients with

neurotoxicity indicate increased permeability of the blood–brain barrier (BBB), and preexisting

neurologic comorbidities are associated with an increased risk of neurotoxicity^{12,13}. Higher tumor

burden and in vivo CAR T-cell numbers resulted in a higher risk of CRS and neurotoxicity^{1,12}. In

our case, CRS and ICANS occurred despite negative MRD. The disruption of the BBB due to

preexisting leukoencephalopathy might have facilitated the transition of activated CAR T-cells

into the CNS¹⁴. The management and treatment of ICANS remain controversial. Researchers

have reported that tocilizumab and/or early corticosteroid administration appears to be more

effective in ICANS management that occurs concurrently with CRS^{3,4,15}, whereas others have

reported the limited efficacy of tocilizumab against ICANS^{2,16}. As the presence of neurological

comorbidities prior to CAR T-cell infusion may increase the risk of ICANS, the time of CAR

T-cell infusion should be carefully determined after neurological conditions have been evaluated.

When neurological comorbidities are in control, CAR T-cell therapy can be initiated while

providing appropriate supportive care and monitoring for neurological adverse events. Further

studies are required to clarify the exact timing of CAR T-cell therapy.

99 **Conflict of interest**

100 The authors declare no conflicts of interest.

101

For Peer Review

References

1. Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. *CNS Drugs* 2018;32:1091-1101.
2. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant* 2019;25:625-638.
3. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. *Nat Rev Clin Oncol* 2018;15:47-62.
4. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med* 2018;378:439-448.
5. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. *Lancet* 2015;385:517-528.
6. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. *Blood* 2017;129:3322-3331.
7. Thompson AA. Transplantation HO, health M. JCAR015 in ALL: A root-cause investigation. *Cancer Discov* 2018;8:4-5.

- 120 8. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a
121 dose-intensive regimen, in adult acute lymphocytic leukemia. *J Clin Oncol* 2000;18:547-561.
- 122 9. Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with
123 low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute
124 lymphoblastic leukaemia: single-arm, phase 2 study. *Lancet Oncol* 2018;19:240-248.
- 125 10. United States Department of Health and Human Services. Common Terminology
126 Criteria for Adverse Events (CTCAE) version 5.0; published 2017.
127 [https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_R](https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf)
128 [eference_8.5x11.pdf](https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf). Accessed July 26, 2020.
- 129 11. Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome
130 associated with the CAR T cell therapy tisagenlecleucel. *J Hematol Oncol* 2018;11:35.
- 131 12. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood–brain barrier
132 disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer*
133 *Discov* 2017;7:1404-1419.
- 134 13. Gust J, Finney OC, Li D, et al. Glial injury in neurotoxicity after pediatric
135 CD19-directed chimeric antigen receptor T cell therapy. *Ann Neurol* 2019;86:42-54.
- 136 14. Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW. Patterns of
137 contrast enhancement in the brain and meninges. *RadioGraphics* 2007;27:525-551.

- 138 15. Mahadeo KM, Khazal SJ, Abdel-Azim H, et al. Management guidelines for paediatric
139 patients receiving chimeric antigen receptor T cell therapy. *Nat Rev Clin Oncol* 2019;16:45-63.
- 140 16. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome
141 associated with novel T cell-engaging therapies. *Cancer J* 2014;20:119-122.

For Peer Review

142 **Figure legends**

143 Figure 1

144 Left row: Axial high-intensity T2/fluid attenuated inversion recovery magnetic resonance image
145 (MRI) shows wide subcortical edema. Right row: axial T1 MRI with gadolinium shows a
146 necrotic-appearing subcortical enhancement pattern. On admission (A, B), after bridging
147 chemotherapy (C, D), day 12 post CAR T-cell infusion (E, F), and day 30 (G, H).

148

149 Supplemental Figure S1

150 Fluorescence-activated cell sorting of cerebrospinal fluid after seizure on day 7 indicates 7.8% of
151 CD3⁺ positive cells were detected as CAR T-cells.



